CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
Cabozantinib +1 moredrug
Likely dose
Cabozantinib 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01630590
NCT01630590Phase 2Completed
CompareCT.gov

An Observational Study of XL-184 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

M.D. Anderson Cancer Center·interventional·Posted Jun 28, 2012·Updated Mar 25, 2022

In Brief

A Phase 2 clinical trial evaluating Cabozantinib and Androgen Ablation Therapy for Prostate Cancer. Completed, enrolled 62 participants across 1 site.

Detailed Summary

The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied. Cabozantinib is designed to block certain proteins in your blood that cause cancer cells to grow. This may cause cancer cells to die.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsExelixis, High Impact Clinical Research Support Program

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 28, 2012
Enrollment StartJan 8, 2014
Primary CompletionApr 6, 2021
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 14.0 years ago

Interventions

Cabozantinibdrug

Starting dose of 60 mg by mouth every day of a 21 day cycle.

Androgen Ablation Therapydrug

Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.